title: Assessment of Anti-Müllerian Hormone Level in Management of Adolescents with Polycystic Ovary Syndrome.
abstract: OBJECTIVE
  This study was oriented to investigate the benefit of anti-Müllerian hormone (AMH) level in the management of polycystic ovary syndrome (PCOS). To assess the impact of metformin and oral contraceptives (OC) on serum AMH levels in a cohort of adolescents with PCOS.
  
  
  METHODS
  Forty-nine adolescents with PCOS were recruited to the study. Twenty-nine patients without insulin resistance were treated with OC (group 1), and 20 patients with insulin resistance were treated with metformin and OC (group 2). AMH and androgen levels were measured prior to and 6 months after the initiation of treatment.
  
  
  RESULTS
  AMH levels were significantly decreased with treatment in both group 1 (p=0.006) and group 2 (p=0.0048). There was a significant correlation between pre- and post-treatment AMH and left ovarian volume (pretreatment: rho=0.336, p=0.018; post-treatment: rho=0.310, p=0.034).
  
  
  CONCLUSIONS
  This study investigated two different treatment regimens in adolescents with PCOS and revealed that AMH levels decreased with treatment. AMH levels were correlated with ovarian volume.
authors.affiliation: Ümraniye Education and Research Hospital, Clinic of Pediatric Endocrinology, İstanbul, Turkey, Phone: +90 505 267 14 03 E-mail: fatmadursun54@yahoo.com.
authors.forename: Fatma
authors.initials: F
authors.lastname: Dursun
authors.forename: Ayla
authors.initials: A
authors.lastname: Güven
authors.forename: Metin
authors.initials: M
authors.lastname: Yıldız
mesh_terms: D000293:Adolescent; D000728:Androgens / Q000097:blood; D054304:Anti-Mullerian Hormone / Q000097:blood*; D015415:Biomarkers / Q000032:analysis; D003277:Contraceptives, Oral, Combined / Q000627:therapeutic use*; D019468:Disease Management; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007333:Insulin Resistance; D008687:Metformin / Q000627:therapeutic use*; D011085:Polycystic Ovary Syndrome / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy*; D011379:Prognosis; D011446:Prospective Studies
chemical_list: D000728:Androgens; D015415:Biomarkers; D003277:Contraceptives, Oral, Combined; D004338:Drug Combinations; D007004:Hypoglycemic Agents; D054304:Anti-Mullerian Hormone; D008687:Metformin